Neratinib Shows Early Activity in EGFR Exon 18–Mutated, Metastatic NSCLC
EDGAR Filing Documents for 0001437749-22-000622
Full article: Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations
SUMMIT (PUMA-NER-5201) Basket Trial
KRAS, HER2 & ALK: targeted options and sequencing issues - memoinOncology
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
208051Orig1s000
Reunion Puma and Da Vinci - gut-aiderbichl.com
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
FP14.15 Neratinib-Based Combination Therapy in HER2-Mutant Lung Adenocarcinomas: Findings from two International Phase 2 Studies - Journal of Thoracic Oncology
KRAS, HER2 & ALK: targeted options and sequencing issues - memoinOncology
PUMA Background
SUMMIT (PUMA-NER-5201) Basket Trial
208051Orig1s000
MB.01 Queen City Basketball Shoes | PUMA
Kam Zaki on Twitter: "an interim analysis of Phase II study (n=14) showed the combination of pyrotinib and apatinib has an ORR of 35.7% when used as second line treatment in patients
2018 Scientific Report
SUMMIT (PUMA-NER-5201) Basket Trial
Targeting HER2 genomic alterations in non-small cell lung cancer - ScienceDirect
SUMMIT (PUMA-NER-5201) Basket Trial
SUMMIT (PUMA-NER-5201) Basket Trial
ADCs Showcase Impressive Activity, Second-Line Combos Seek to Raise the Bar in Quest to Target HER2+ NSCLC
Neratinib Chapter
Targeting HER2 genomic alterations in non-small cell lung cancer - ScienceDirect
Targeting HER2 genomic alterations in non-small cell lung cancer - ScienceDirect
SUMMIT (PUMA-NER-5201) Basket Trial
